Brief: Erytech Announces Completion Of Enrollment In TRYBECA-1 Phase 3 Trial

Phaxiam Therapeutics SA

15/12/2020 06:55

Dec 15 (Reuters) - Erytech Pharma  ERYP.PA :
    * ANNOUNCED ON MONDAY COMPLETION OF ENROLLMENT IN THE
TRYBECA-1
PHASE 3 TRIAL IN SECOND-LINE PANCREATIC CANCER
    * A TOTAL OF 510 PATIENTS PARTICIPATED IN THE TRIAL,
SLIGHTLY
ABOVE THE TARGET ENROLLMENT OF 482 PATIENTS
    * INTERIM SUPERIORITY ANALYSIS EXPECTED IN Q1 2021; FINAL
ANALYSIS
IN Q4 2021
    * EXPECTS TO FILE FOR REGULATORY APPROVAL IN THE UNITED
STATES AND
IN EUROPE IN THE SECOND HALF OF 2021

 Source text for Eikon:  urn:newsml:reuters.com:*:nGNX3Y1qvq
    
 Further company coverage:  ERYP.PA  
   


 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00))